SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
Sodium/glucose cotransporter 1 (SGLT1), an essential active glucose transport protein that helps maintain high intracellular glucose levels, was previously shown to interact with epidermal growth factor receptor (EGFR); the SGLT1–EGFR interaction maintains intracellular glucose levels to promote sur...
Main Authors: | Huiquan Liu, Ayse Ertay, Ping Peng, Juanjuan Li, Dian Liu, Hua Xiong, Yanmei Zou, Hong Qiu, David Hancock, Xianglin Yuan, Wei‐Chien Huang, Rob M. Ewing, Julian Downward, Yihua Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12530 |
Similar Items
-
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
by: Brooke N. McKnight, et al.
Published: (2020-04-01) -
SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01) -
SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01) -
Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
by: Nitesh D. Kuhadiya, et al.
Published: (2021-04-01) -
Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
by: Zhen Wang, et al.
Published: (2021-01-01)